Currently, Bionano Genomics Inc [BNGO] is trading at $1.05, down -0.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The BNGO shares have gain 5.26% over the last week, with a monthly amount drifted -7.89%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, April 2024, Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules. In a post published today on Yahoo Finance, Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will be exercisable immediately upon issuance, have an exercise price of $1.02 per share and expire five years from the date of issuance. The closing of the offering is expected to occur on or about April 8, 2024, subject to the satisfaction of customary closing conditions.
From an analyst’s perspective:
Bionano Genomics Inc [NASDAQ: BNGO] stock has seen the most recent analyst activity on January 05, 2023, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $4. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $10 on June 16, 2021. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $1.25 as its price target on September 24, 2020. Oppenheimer started tracking with a Outperform rating for this stock on April 08, 2020, and assigned it a price target of $1.50.
This stock has fluctuated between a low of $0.96 and a high of $11.80 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $262.5 within the next 12 months. Bionano Genomics Inc [NASDAQ: BNGO] shares were valued at $1.05 at the most recent close of the market. An investor can expect a potential return of 24900.0% based on the average BNGO price forecast.
Analyzing the BNGO fundamentals
Trailing Twelve Months sales for Bionano Genomics Inc [NASDAQ:BNGO] were 36.12M which represents 30.51% growth. Gross Profit Margin for this corporation currently stands at 0.26% with Operating Profit Margin at -5.82%, Pretax Profit Margin comes in at -6.44%, and Net Profit Margin reading is -6.44%. To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is -1.41 and Total Capital is -1.84. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0233 points at the first support level, and at 0.9967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0933, and for the 2nd resistance point, it is at 1.1367.
Bionano Genomics Inc [BNGO] reported earnings per share of -$3.22 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.97/share, meaning a difference of -$2.25 and a surprise factor of -232.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.24 per share as compared to estimates of -$1.03 per share, a difference of -$0.21 representing a surprise of -20.40%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bionano Genomics Inc [NASDAQ:BNGO] is 1.40. On the other hand, the Quick Ratio is 1.17, and the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 1.59, the price to book ratio is 0.50.
Transactions by insiders
Recent insider trading involved Mamuszka Hannah, Director, that happened on Jun 13 ’23 when 65789.0 shares were purchased. President and CEO, Holmlin R. Erik completed a deal on May 16 ’23 to buy 15000.0 shares. Meanwhile, Chief Financial Officer Stewart Christopher P. bought 50000.0 shares on May 12 ’23.
